Event dossier

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

1 report1 sourceMar 25, 2026, 2:38 PM
FilterCNBC
Clustered coverageCNBC
Coverage timeline1
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

CNBCMar 25, 2026, 2:38 PM

Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipeline

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.

El Psy Congroo Newswire